Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical brimonidine to reduce post-inflammatory response after IPL treatment in facial telangiectasias
2015-004789-27Phase 4Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of brimonidine in telangiectasia, Postinflammatory erythema (PIE) and postprocedural pain (CPSP) (2 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Reduction of IPL-induced inflammatory response with brimonidine. Started Dec 2015; status: completed.
02
Drugs
brimonidine
03
Conditions
telangiectasiaPostinflammatory erythema (PIE)postprocedural pain (CPSP)
Beyond the preview
Go deeper on 2015-004789-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004789-27.